Erlotinib Completed Phase 2 Trials for Fallopian Tube Cancer / Recurrent Ovarian Epithelial Cancer / Primary Peritoneal Cavity Cancer / Stage IV Ovarian Epithelial Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00126542Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer